Main content

    Prostate Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Adjuvant Therapy  |  Metastatic Prostate Cancer


    Active Trials

    Adjuvant Therapy

    Title: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
    Description: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
    Investigators: NCI - National Cancer Institute
    Eligibility: Male subjects who have histologic documentation of prostatic cancer
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study CALGB 90203

    Back to top

    Active Trials

    Metastatic Prostate Cancer

    Title: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
    Description: This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with prostate cancer that has spread to other parts of the body
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects, 18 y/o and older, with metastatic adenocarcinoma of the prostate
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study NRG-BR001

    Title: A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Description: This study is to compare the radiographic progression-free survival (rPFS) of JNJ56021927 in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm])
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with a clinical diagnosis of adenocarcinoma of the prostate
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Janssen PCR3001

    Title: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
    Description: The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with a clinical diagnosis of metastatic prostate cancer
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study S1216

    Title: A Phase Ib/II Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
    Description: Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with histologically or cytologically confirmed metastatic or advanced prostate adenocarcinoma that has been previously treated with docetaxel and has progressed during treatment of at least one hormonal therapy
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study Genentech GO27983

    Title: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
    Description: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with a histologically confirmed adenocarcinoma of the prostate diagnosed within the past 180 days and at intermediate-risk for recurrence
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study RTOG 0815

    Title: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
    Description: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with a pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study RTOG 0924

    Title: Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
    Description: This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with progressive castration-resistant metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Alliance A031201

    • updated July 2015

    Back to top